RDNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy RDNT now. Price (70.6) is sitting just above key support (69.94) after a short-term selloff/weak tape, while the medium-term fundamental and Street setup remains bullish (multiple Buy/Overweight ratings and $86–$92 targets). Even though near-term momentum is still negative (MACD) and options flow is put-heavy, the risk/reward favors an immediate entry for an impatient buyer looking for a rebound off support and participation in the longer uptrend catalysts (outpatient shift + AI imaging).
RDNT is in a short-term down-move/weak momentum phase: MACD histogram is negative (-0.245) and expanding to the downside, which typically signals bearish momentum is still in control. However, RSI(6) at ~27 is effectively oversold (despite the label shown), often consistent with late-stage selling and rebound potential. Moving averages are converging (trend indecision/base-building). Key levels: Support S1 ~69.94 then S2 ~68.61; Resistance pivot ~72.08 then R1 ~74.22. With price at 70.6, the stock is very close to support—technically a reasonable buy zone for a bounce, with the first upside test near 72–74.
Strong structural tailwinds highlighted by analysts: hospital-to-outpatient shift and increasing demand for advanced imaging;
AI-related benefits/ramp called out by KeyBanc;
Hedge funds are accumulating (buying amount up ~139% last quarter), supportive of medium-term upside;
Pattern-based projection included in the data implies a positive 1-month skew (+3.5% next month) even after near-term weakness.
Near-term momentum remains bearish (negative, expanding MACD) and pre-market is down (-1.56%), so weakness can persist before any rebound;
Options flow is put-heavy (high put volume), implying traders are braced for downside in the short run;
Prior short report narrative (even if disputed) can periodically pressure sentiment;
Profitability quality flag: gross margin declined sharply YoY in the latest quarter snapshot.
Latest reported quarter: 2025/Q3. Revenue grew to ~$522.9M (+13.39% YoY). Net income increased to ~$5.42M (+68.81% YoY) and EPS rose to $0.07 (+75% YoY), indicating improving bottom-line performance. The main blemish is gross margin dropping to ~6.25 (down ~43.9% YoY), which signals cost/expense pressure or mix effects even as revenue and earnings grew.
Recent Street trend is clearly positive: multiple bullish reiterations/raises and a fresh initiation. KeyBanc initiated Overweight with a $92 target (Jan 2026). Barclays raised PT to $86 (Nov 2025) and kept Overweight. Truist raised PT to $90 and kept Buy. Raymond James maintained Strong Buy while pushing back on a short report, framing concerns as largely already-known/overblown. Wall St pros: strong tailwinds (outpatient imaging demand), credible multi-year growth targets, and AI upside. Cons: debate around same-store growth optics/closures narrative and near-term margin pressure.
